Fortis Healthcare Ltd Q1 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Published 5 Aug 2026 | Healthcare Services | Market Cap: ₹69.8K Cr

Hospital revenue expected to grow with addition of ~900 beds in FY26; about 50% to be operationalized within the year. Hospital business: Expecting 2% margin improvement over the year; strong first quarter and new brownfield capacity expansions could support this (Page 7, 16). - Diagnostics business: Margin guidance around 22%-23% for the full year; growth projected at high single digits (around 9%-10%) in next few quarters moving towards low double digits in 6-8 quarters (Pages 7, 16). - Revenue growth: Hospital revenues grew 18.6% YoY; Diagnostics net revenue grew 6.3% YoY with improving operating EBITDA (Page 3). - ARPOB growth in hospital business expected around 5%-6%, supported by increasing share of complex cases and robotic surgeries growing at 50%-75% YoY (Pages 4, 13, 14). - Addition of approx.

From Fortis Healthcare Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.

Price

₹907

Market Cap

₹69.8K Cr

P/E Ratio

66.1

How does Fortis Healthcare Ltd rank in Healthcare Services?

Compare Fortis Healthcare Ltd against every Healthcare Services company this quarter on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

Fortis Healthcare Ltd — Quarterly revenue & net profit

Revenue Net Profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹2.4K Cr, net profit ₹271 Cr.

Full financials →

📊 Revenue & Sales Performance

→Hospital revenue expected to grow with addition of ~900 beds in FY26; about 50% to be operationalized within the year.
→Ramp-up of Manesar facility anticipated to reach EBITDA breakeven soon with increasing monthly revenue.
→ARPOB (Average Revenue Per Occupied Bed) growth projected around 5-6%, driven by day care, OPD, and robotic surgeries.
→Oncology revenue growing at ~27-28% CAGR; contribution currently about 17-20% of total hospital revenue.
→Robotic surgeries showing 75% YoY growth; expected to grow at ~50% next year with addition of new robotic machines.
→Diagnostics gross revenue grew 7.4% YoY; operating EBITDA margins expected around 22-23% for the year.
→Diagnostics volume growth ~5% with revenue growth moving from high single-digit towards early double-digit within 6-8 quarters.
→International business revenue grew 21% YoY and expected to continue positive trend.
→Organic and inorganic diagnostic expansion expected regionally without restricting to specific geographies.

📈 Profitability & Margins

→Hospital business: Expecting 2% margin improvement over the year; strong first quarter and new brownfield capacity expansions could support this (Page 7, 16).
→Diagnostics business: Margin guidance around 22%-23% for the full year; growth projected at high single digits (around 9%-10%) in next few quarters moving towards low double digits in 6-8 quarters (Pages 7, 16).
→Revenue growth: Hospital revenues grew 18.6% YoY; Diagnostics net revenue grew 6.3% YoY with improving operating EBITDA (Page 3).
→ARPOB growth in hospital business expected around 5%-6%, supported by increasing share of complex cases and robotic surgeries growing at 50%-75% YoY (Pages 4, 13, 14).
→Addition of approx. 900 beds planned this year, with rapid ramp-up expected, contributing significantly to revenue in coming years (Pages 11, 14).
→Overall expectation of continued positive trajectory in revenue and profitability leveraging network expansion and operational efficiencies (Pages 3, 5, 16).

🏗️ Capital Expenditure Plans

→Fortis Healthcare currently has approximately 15 robotic machines across its network and plans to add 4 more this year.
→Each da Vinci robotic machine costs around INR 12 crores, while orthopedic robots cost about INR 5 crores.
→The company is investing in oncology setups, adding oncology services to hospitals where it is currently not available, expecting continued oncology growth of about 27-28% CAGR.
→Brownfield expansions include adding about 450 beds in Mohali, 250 beds in Jalandhar, and 180 beds in Amritsar.
→A new 200-bed facility is planned for Manesar, and capacity additions are planned at Noida (including a 60-bed addition), Faridabad, and other locations.
→Fortis has acquired the SRL brand to strengthen its diagnostic business.
→The company has entered into an operations and maintenance agreement for 700 beds at Gleneagles India, expanding its operational footprint and seeking operational synergies.

💰 Fundraising & Capital Structure

- The company’s net debt as of June 30, 2025, is INR 1,869 crores with a net debt-to-EBITDA ratio of 0.92x, up from 0.22x on June 30, 2024. - The increase in debt was primarily due to funds raised to part finance the acquisition of a 31.5% private equity stake in Agilus Diagnostics and acquisition of the Fortis brand and trademarks. - There is no explicit mention of any current or planned new fundraising through debt or equity in the provided transcript. - The management has highlighted a disciplined approach toward acquisitions and a cautious stance on future investments. - Any future fundraising, if undertaken, will be done in a transparent and arm’s length manner. No specific planned or ongoing debt/equity fundraising beyond mentioned acquisitions was disclosed.

📋 Order Book & Pipeline

The transcript does not provide explicit details on current or expected orderbook or pending orders for Fortis Healthcare Limited. However, relevant points on operational expansions and future plans include: - Acquisition of Shrimann Superspecialty Hospital in Jalandhar, Punjab, adding 228 beds with potential expansion to 450 beds. - Operation and maintenance agreement with Gleneagles India managing approx. 700 beds across 5 hospitals and a clinic. - Planned addition of 900 beds in the current year, including brownfield expansions and new facilities like Manesar. - Expectations of ramp-up in new beds leading to significant revenue growth next year. No specific figures or commentary on orderbook or pending orders were mentioned during the call.

Key Metrics

What Fortis Health.'s management said in earlier quarters

Others in Healthcare Services this season

Aster DM Quality (Q1 FY26)
Recent quarters saw subdued volume growth due to leadership changes and seasonal effects, but an 8% volume growth was achieved in Q1 FY26, improving from 2% in…
Dr Agarwals Health Care Ltd (Q1 FY26)
70 crores via preferential allotment to AEHL for CAPEX plans, particularly the flagship facility at Cathedral Road, indicating capacity and service…
Syngene International Ltd (Q1 FY26)
Operating EBITDA grew 21% YoY in Q1 FY '26 with margins rising to ~24% from 22% last year. Key concall takeaways from Syngene International Ltd's Q1 FY26…
Yatharth Hospital & Trauma Care Services Ltd (Q1 FY26)
International patient business is growing but will remain around 10% of revenue, positively impacting ARPOB without hurting margins. Key concall takeaways from…

Compare:vs Apollo Hospitals Enterprise Ltd vs Max Healthcare vs Aster DM Quality

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Fortis Healthcare Ltd Q1 FY26 results?

What is Fortis Healthcare Ltd share price analysis?

Fortis Healthcare Ltd currently shows a neutral. The stock trades at a P/E of 66.1 with a market cap of ₹69,834 Cr. Investors should review the full earnings analysis for detailed insights.

Is Fortis Healthcare Ltd planning capital expenditure?

Fortis Healthcare currently has approximately 15 robotic machines across its network and plans to add 4 more this year.

Keep Fortis Healthcare Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.